OSE 127

Drug Profile

OSE 127

Alternative Names: Anti CD127 monoclonal antibody - OSE Immunotherapeutics; Anti interleukin-7 receptor-α monoclonal antibody - OSE Immunotherapeutics; Effi-7; IL-7 receptor antagonist - OSE Immunotherapeutics; Interleukin-7 receptor antagonist - OSE Immunotherapeutics; OSE-127

Latest Information Update: 10 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Effimune
  • Developer INSERM; OSE Immunotherapeutics; PX Therapeutics
  • Class Anti-inflammatories; Antineoplastics; Antiulcers; Monoclonal antibodies
  • Mechanism of Action Interleukin 7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation; Precursor T-cell lymphoblastic leukaemia-lymphoma; Transplant rejection; Ulcerative colitis
  • Research Sjogren's syndrome

Most Recent Events

  • 07 May 2018 OSE Immunotherapeutics plans a phase II trial in Autoimmune bowel disease and Sjogren's syndrome
  • 26 Oct 2017 OSE Immunotherapeutics plans a phase II trial for Ulcerative colitis by end-2018
  • 23 May 2017 OSE Immunotherapeutics extends its agreement with Selexis for clinical development of OSE 127
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top